Cocrystal hydrate of kaempferol–cilostazol, antioxidant, cytotoxicity and lipid accumulation inhibition effects
RSC Pharmaceutics · 2026
DOI: 10.1039/d6pm00025h ↗Kurz gefasst
Fachartikel in der Zeitschrift RSC Pharmaceutics, 2026. Verfasst von Shiyu Chen und 7 weiteren Autor:innen. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Cilostazol (CS) can improve chronic atherosclerosis by inhibiting vascular endothelial hyperplasia, inhibiting platelet aggregation, enhancing vasodilation, and reducing plasma triglycerides.
Zitieren
APA
Chen, S., Qian, K., Pan, R., Yang, J., Ma, Y., Xu, Y., Ye, Y., & Yuan, H. (2026). Cocrystal hydrate of kaempferol–cilostazol, antioxidant, cytotoxicity and lipid accumulation inhibition effects. RSC Pharmaceutics. https://doi.org/10.1039/d6pm00025h
Vancouver
Chen S, Qian K, Pan R, Yang J, Ma Y, Xu Y, et al. Cocrystal hydrate of kaempferol–cilostazol, antioxidant, cytotoxicity and lipid accumulation inhibition effects. RSC Pharmaceutics. 2026. doi:10.1039/d6pm00025h
BibTeX
@article{Chen2026,
author = {Chen, Shiyu and Qian, Kun and Pan, Rongbin and Yang, Jie and Ma, Yuexing and Xu, Yuqing and Ye, Yaohui and Yuan, Huaan},
title = {Cocrystal hydrate of kaempferol–cilostazol, antioxidant, cytotoxicity and lipid accumulation inhibition effects},
journal = {RSC Pharmaceutics},
year = {2026},
doi = {10.1039/d6pm00025h}
}
EUVIMED